



---

**Date:** July 12, 2019

**Re:** Reference materials regarding KHI Issue Brief, *Medical Marijuana: Policy Considerations (April 2019)*, KHI/19-24

**Prepared by:** D. Charles Hunt, M.P.H.

---

## **Introduction**

Atakan, Z. (2012). Cannabis, a complex plant: Different compounds and different effects on individuals. *Therapeutic Advances in Psychopharmacology*, 2(6), 241-254.

Centers for Disease Control and Prevention. (n.d.). What is marijuana? Retrieved from <https://www.cdc.gov/marijuana/faqs/what-is-marijuana.html>

Iseger, T. A., & Bossong, M. G. (2015). A systematic review of the antipsychotic properties of cannabidiol in humans. *Schizophrenia Research*, 162(1-3), 153-161.

National Institute on Drug Abuse. (2018). *Marijuana*. Retrieved from <https://www.drugabuse.gov/publications/research-reports/marijuana>

United States Department of Agriculture Economic Research Service. (2000). *Industrial hemp in the United States: Status and market potential* (Report No. AGES-001E). Washington, DC: U.S. Department of Agriculture. Retrieved from <https://www.ers.usda.gov/publications/pub-details/?pubid=41757>

World Health Organization (2018). Cannabis plant and cannabis resin. In World Health Organization, *WHO Expert Committee on Drug Dependence, fortieth report: (WHO Technical Report Series, No. 1013)*. Geneva, Switzerland: World Health Organization. Retrieved from <https://apps.who.int/iris/bitstream/handle/10665/279948/9789241210225-eng.pdf?ua=1>

## **State Marijuana Laws**

Bestrashniy, J., & Winters, K. C. (2015). Variability in medical marijuana laws in the United States. *Journal of the Society of Psychologists in Addictive Behaviors*, 29(3), 639–642.

Ghosh, T., Van Dyke, M., Maffey, A., Whitley, E., Gillim-Ross, L., & Wolk, L. (2016). The public health framework of legalized marijuana in Colorado. *American Journal of Public Health*, 106(1), 21-27.

National Conference of State Legislatures. (2019). *State medical marijuana laws*. Retrieved from <http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx>

National Conference of State Legislatures. (2019). *Marijuana overview*. Retrieved from <http://www.ncsl.org/research/civil-and-criminal-justice/marijuana-overview.aspx>

## **Kansas Efforts to Legalize Medical Marijuana**

Bruno, J. (2018, June 28). CBD business owners preparing to open medical marijuana dispensaries. *Oklahoma News 4*. Retrieved from <https://kfor.com/2018/06/28/cbd-business-owners-preparing-to-open-medical-marijuana-dispensaries/>

Kansas Legislative Research Department. (2016). *Amending the crimes of possession of marijuana, theft, and burglary, Kan. H. B. 2462*. Retrieved from [http://www.kslegislature.org/li\\_2016/b2015\\_16/measures/documents/summary\\_hb\\_2462\\_2016.pdf](http://www.kslegislature.org/li_2016/b2015_16/measures/documents/summary_hb_2462_2016.pdf)

Kansas Division of the Budget. (2017, February 07). *Fiscal Note: S. B. 112*. Retrieved from [http://www.kslegislature.org/li/b2017\\_18/measures/documents/fisc\\_note\\_sb112\\_00\\_0000.pdf](http://www.kslegislature.org/li/b2017_18/measures/documents/fisc_note_sb112_00_0000.pdf)

Kansas Division of the Budget. (2018, January 12). *Fiscal Note: S. B. 263*. Retrieved from [http://kslegislature.org/li/b2017\\_18/measures/documents/fisc\\_note\\_sb263\\_00\\_0000.pdf](http://kslegislature.org/li/b2017_18/measures/documents/fisc_note_sb263_00_0000.pdf)

Kansas Legislative Research Department. (2016). *Summary of Bill: H. B. 2462*. Retrieved from [http://www.kslegislature.org/li\\_2016/b2015\\_16/measures/documents/hb2462\\_00\\_0000.pdf](http://www.kslegislature.org/li_2016/b2015_16/measures/documents/hb2462_00_0000.pdf)

Kansas Legislative Research Department. (2018). Legalization of medical and recreational marijuana: History of legislation in Kansas. *Kansas Legislator Briefing Book 2018* (Section D-3). Retrieved from [www.kslegresearch.org/KLRD-web/Publications/BriefingBook/2018Briefs/D-3-LegalizationofMedicalandRecreationalMarijuana.pdf](http://www.kslegresearch.org/KLRD-web/Publications/BriefingBook/2018Briefs/D-3-LegalizationofMedicalandRecreationalMarijuana.pdf)

Kansas Legislative Research Department. (2017). Crimes and criminal matters. Summary of Bill: S. B. 112. *2017 Summary of Legislation* (32-33). Retrieved from [http://www.kslegresearch.org/KLRD-web/Publications/SummaryofLegislation/2017\\_summary\\_of\\_legislation.pdf](http://www.kslegresearch.org/KLRD-web/Publications/SummaryofLegislation/2017_summary_of_legislation.pdf)

Kansas Legislative Research Department. (2018). Agriculture and natural resources. Summary of Bill: S. B. 263. *2018 Summary of Legislation* (1-3). Retrieved from [http://www.kslegresearch.org/KLRD-web/Publications/SummaryofLegislation/2018\\_summary\\_of\\_legislation.pdf](http://www.kslegresearch.org/KLRD-web/Publications/SummaryofLegislation/2018_summary_of_legislation.pdf)

LaVito, A. (2018, September 27). DEA reschedules Epidiolex, marijuana-derived drug, paving the way for it to hit the market. *CNBC*. Retrieved from <https://www.cnbc.com/2018/09/27/dea-schedules-epidiolex-allowing-gw-pharma-to-start-selling-the-drug.html>

New Frontier Data. (2016). *The CBD report*. Denver, CO: Hemp Business Journal.

Ranker, L. (2018, September 2). Cannabis is booming in Topeka, but these products won't get you high. *The Topeka Capital-Journal*. Retrieved from <https://www.cjonline.com/news/20180901/cannabis-is-booming-in-topeka-but-these-products-wont-get-you-high>

Kansas Legislative Research Department (2017). Summary of Bill: S. B. 112. Retrieved from: [http://www.kslegislature.org/li/b2017\\_18/measures/documents/sb112\\_00\\_0000.pdf](http://www.kslegislature.org/li/b2017_18/measures/documents/sb112_00_0000.pdf)

Substance Abuse and Mental Health Services Administration. (2016). *2015-2016 NSDUH state-specific tables*. Retrieved from <https://www.samhsa.gov/data/report/2015-2016-nsduh-state-specific-tables>

Substance Abuse and Mental Health Services Administration. (2016). *NSDUH p-value tables*. Retrieved from <https://www.samhsa.gov/data/report/p-value-tables-0>

United States Drug Enforcement Administration. (n.d.) *Drug scheduling*. Retrieved from <https://www.dea.gov/drug-scheduling>

### **Therapeutic Effects and Health Risks of Marijuana Use**

Allegretti, J. R., Courtwright, A., Lucci, M., Korzenik, J. R., & Levine, J. (2013). Marijuana use patterns among patients with inflammatory bowel disease. *Inflammatory Bowel Disorder*, 19(13), 2809-2814.

Alzheimer's Association. (2018). Alzheimer's disease facts and figures. *Alzheimer's & Dementia*, 14(3) 367-429.

Centers for Disease Control and Prevention. (2015). *Epidemiology of the IBD*. Retrieved from <https://www.cdc.gov/ibd/IBD-epidemiology.htm>

Dhadwal, G. & Kirchhof, M. G. (2017). The risks and benefits of cannabis in the dermatology clinic. *Journal of Cutaneous Medicine and Surgery*, 22(2), 194-199.

Hasenoehrl, C., Storr, M., & Schicho, R. (2017). Cannabinoids for treating inflammatory bowel diseases: Where are we and where do we go? *Expert Review of Gastroenterology & Hepatology*, 11(4), 329-337.

Kansas Department of Health and Environment. (2018). *HIV in Kansas: Annual report for January 1 – December 31, 2017*. Retrieved from [http://www.kdheks.gov/sti\\_hiv/update\\_newsletter/CY\\_2017\\_Annual\\_Tables.pdf](http://www.kdheks.gov/sti_hiv/update_newsletter/CY_2017_Annual_Tables.pdf)

Kappelman, M. D., Moore, K. R., Allen, J. K., & Cook, S. F. (2013). Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured U.S. population. *Digestive Diseases and Sciences*, 58(2), 519-525.

Kappelman, M. D., Rifas-Shiman, S. L., Kleinman, K., Ollendorf D., Bousvaros A., Grand R.J., et al. (2007). The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. *Clinical Gastroenterol and Hepatology*, 5(12), 1424-1429.

- Lim, M., & Kirchhof, M. G. (2018). Dermatology-related uses of medical cannabis promoted by dispensaries in Canada, Europe and the United States. *Journal of Cutaneous Medicine and Surgery*, 23(2) 178-184.
- Ijaopo, E. O. (2017). Dementia-related agitation: A review of non-pharmacological interventions and analysis of risks and benefits of pharmacotherapy. *Translational Psychiatry*, 7(10), e1250.
- Loftus, E. V. Jr. (2004). Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. *Gastroenterology*, 126(6), 1504-1517.
- Mehta, P., Kaye, W., Bryan, L., Larson, T., Copeland, T., Wu, J., et al. (2016). Prevalence of amyotrophic lateral sclerosis – United States, 2012-2013. *Morbidity and Mortality Weekly Report Surveillance Summaries*, 65(8), 1-12.
- Nahin, R. L. (2015). Estimates of pain prevalence and severity in adults: United States, 2012. *The Journal of Pain*, 16(8), 769-780.
- National Academies of Sciences, Engineering and Medicine. (2017). *The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research*. Washington, DC: The National Academies Press.
- National Cancer Institute, DCCPS, Surveillance Research Program, Data Modeling Branch. (2018). *Surveillance, Epidemiology, and End Results (SEER) Program prevalence database: "SEER 9, 40 Yr Limited Duration Prevalence on 1/1/2015"* [Data file]. Available from <https://seer.cancer.gov>
- National Institutes of Health. (2013). *Genetics home reference: Nail patella syndrome*. Retrieved from <https://ghr.nlm.nih.gov/condition/nail-patella-syndrome#>
- National Multiple Sclerosis Society. (2018). *Prevalence of MS more than doubles estimate*. Retrieved from <https://www.nationalmssociety.org/About-the-Society/MS-Prevalence>
- Prevent Blindness America. (2012). *Vision problems in the U.S.: Prevalence of adult vision impairment and age-related eye disease in America*. Retrieved from <http://www.visionproblemsus.org/index.html>
- Rosenberg, E. S., Hall, E. W., Sullivan, P. S., Sanchez, T. H., Workowski, K. A., Ward, J. W., et al. (2017). Estimation of state-level prevalence of hepatitis C virus infection, U.S. states and District of Columbia, 2010. *Clinical Infectious Diseases*, 64(11), 1573-1581.
- von Haehling, S. & Ander, S. D. (2014). Prevalence, incidence and clinical impact of cachexia: facts and numbers – update 2014. *Journal of Cachexia, Sarcopenia and Muscle*, 5(4), 261-263.
- Zack, M. M. & Kobau, R. (2017). National and state estimates of the numbers of adults and children with active epilepsy – United States, 2015. *Morbidity and Mortality Weekly Report*, 66(31), 821-825.

Wallin, M. (2017). The prevalence of multiple sclerosis in the United States: A population-based healthcare database approach. *European Committee for Treatment and Research in Multiple Sclerosis, 19999*(p344). Retrieved from <https://onlinelibrary.ectrims-congress.eu/ectrims/2017/ACTRIMS-ECTRIMS2017/199999/mitchell.t.wallin.the.prevalence.of.multiple.sclerosis.in.the.united.states.a.html>

### **Impact on Driving under the Influence, Traffic Crashes and Fatalities**

- Anderson, D. M., Hansen, B., & Rees, D. I. (2013). Medical marijuana laws, traffic fatalities, and alcohol consumption. *Journal of Law and Economics, 56*(2), 333-369.
- Aston, E. R., Merrill, J. E., McCarthy, D. M., & Metrik, J. (2016). Risk factors for driving after and during marijuana use. *Journal of Studies on Alcohol and Drugs, 77*(2), 309-316.
- Aydelotte, J. D., Brown, L. H., Luftman, K. M., Mardock, A. L., Teixeira, P. G. R., Coopwood, B., et al. (2017). Crash fatality rates after recreational marijuana legalization in Washington and Colorado. *American Journal of Public Health, 107*(8), 1329-1331.
- Berg, C. J., Daniel, C. N., Vu, M., Li, J., Martin, K., Le, L. (2018). Marijuana use and driving under the influence among young adults: A socioecological perspective on risk factors. *Substance Use & Misuse, 53*(3), 370-380.
- Chihuri, S., Li, G., Chen, Q. (2017). Interaction of marijuana and alcohol on fatal motor vehicle crash risk: A case–control study. *Injury Epidemiology 4*(8).
- Compton, R. (2017). *Marijuana-impaired driving - A report to Congress*. (DOT HS 812 440). Washington, DC: National Highway Traffic Safety Administration.
- United States Government Accountability Office (2015). *Drug–impaired driving – Additional support needed for public awareness initiatives*. (Report No. GAO-15-293). Washington, DC: United States Government Accountability Office. Retrieved from <https://www.gao.gov/assets/670/668622.pdf>
- Hansen, B., Miller, K., & Weber, C. (2019). Early evidence on recreational marijuana legalization and traffic fatalities. *Economic Inquiry*. Advance online publication. doi:10.1111/ecin.12751
- Huestis, M. A. (2015). Deterring driving under the influence of cannabis. *Society for the Study of Addiction, 110*(11), 1697-1698.
- Kim, J. H., Santaella-Tenorio, J., Mauro, C., Wrobel, J., Cerd`a, M., Keyes, K.M., et al. (2016). State medical marijuana laws and the prevalence of opioids detected among fatally injured drivers. *American Journal of Public Health, 106*(11), 2032-2037.
- Logan, B., Kacinko, S. L., & Beirness, D. J. (2016). *An evaluation of data from drivers arrested for driving under the influence in relation to per se limits for cannabis*. Washington, DC: AAA Foundation for Traffic Safety.
- Monfort, S. S. (2018). *Effect of recreational marijuana sales on police-reported crashes in Colorado, Oregon, and Washington*. Arlington, VA: Insurance Institute for Highway Safety.

- Neavyn, M. J., Blohm, E., Babu, K. M., & Bird, S. B. (2014). Medical marijuana and driving: A review. *Journal of Medical Toxicology*, *10*, 269–279.
- Santaella-Tenorio, J., Mauro, C. M., Wall, M. M., Kim, J. H., Cerdá, M., Keyes, K. M., et al. (2017). US traffic fatalities, 1985–2014, and their relationship to medical marijuana laws. *American Journal of Public Health*, *107*(2), 336–342.
- Scherer, M., Canham, S., Voas, R. B., & Furr-Holden, C. D. (2018). Intercorrelation of alcohol and other drug use disorders among a national sample of drivers. *Journal of Psychoactive Drugs*, *50*(2), 143–150.
- Sevigny, E. L. (2018). The effects of medical marijuana laws on cannabis-involved driving. *Accident Analysis and Prevention*, *118*, 57–65.
- Whitehill, J. M., Rivara, F. P., & Moreno, M. A. (2014). Marijuana-using drivers, alcohol-using drivers and their passengers: Prevalence and risk factors among underage college students. *Journal of the American Medical Association Pediatrics*, *168*(7), 618–624.
- Wong, K., Brady, J. E., Li, G. (2014). Establishing legal limits for driving under the influence of marijuana. *Injury Epidemiology*, *1*(1), 26.

### **Marijuana-Related Exposures Reported to Poison Control Centers**

- Berger, E. (2014). Legal marijuana and pediatric exposure. *Annals of Emergency Medicine*, *64*(4), A19–A21.
- Colorado Department of Public Health and Environment. (2017). *Monitoring health concerns related to marijuana in Colorado: 2016*. Denver, CO: Colorado Department of Public Health and Environment. Retrieved from <https://drive.google.com/file/d/0B0tmPQ67k3NVQIFnY3VzZGVmdFk/view>
- Friedenberg, L., & Smith, G. (2014). Pediatric marijuana exposure. *Pediatrics for Parents*, *30*(9), 3.
- Freedman, D. A., & Patel, A. D. (2018). Inadequate regulation contributes to mislabeled online cannabidiol products. *Pediatric Neurology Briefs*, *32*, 3.
- Gourdet, C., Giombi, K. C., Kosa, K., Wiley, J., & Cates, S. (2017). How four U.S. states are regulating recreational marijuana edibles. *International Journal of Drug Policy*, *43*, 83–90.
- Grossman, E. R., Gonzalez-Nahm, S., Frost, N., & Benjamin-Neelon, S. E. (2018). Childcare providers' possession or use of marijuana, tobacco, or alcohol while caring for children: A comparison of U.S. state regulations. *American Journal of Public Health*, *108*(6), 748–753.
- Gummin, D. D., Mowry, J. B., Spyker, D. A., Brooks, D. E., Fraser, M. O., & Banner, W. (2016). Annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 34th Annual Report. *Clinical Toxicology*, *55*(10) 1072–1252.
- Heard, K., Marlin, M. B., Nappe, T., & Hoyte, C. O. (2017). Common marijuana-related cases encountered in the emergency department. *American Journal Health-System Pharmacy*, *74*(22), 1904–1908.

- Lovecchio, F., & Heise, C. W. (2015). Accidental pediatric ingestions of medical marijuana: A 4-year poison center experience. *American Journal of Emergency Medicine*, 33(6), 844–845.
- Nappe, T. M., & Hoyte, C. O. (2017). Pediatric death due to Myocarditis after exposure to cannabis. *Clinical Practice and Cases in Emergency Medicine*, 1(3), 166–170.
- National Academies of Sciences, Engineering, and Medicine. (2017). The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. Washington, DC: The National Academies Press.
- Reed, J. (2016). *Marijuana legalization in Colorado: Early findings - A report pursuant to Senate Bill 13-283*. Denver, CO: Colorado Department of Public Safety.
- Richards, J. R., Smith, N. E., & Moulin, A. K. (2017). Unintentional cannabis ingestion in children: A systematic review. *Journal of Pediatrics*, 190, 142–152.
- Silva, A., & Parsh, B. (2014). Pediatric emergency: Unintended marijuana ingestion. *Nursing2014*, 44(11), 12-13.
- Thomas, A. A., & Mazor, S. (2017). Unintentional marijuana exposure presenting as altered mental status in the pediatric emergency department: A case series. *Journal of Emergency Medicine*, 53(6), e119–e123.
- Thomas, A. A., Moser, E., Dickerson-Young, T., & Mazor, S. (2017). A review of pediatric marijuana exposure in the setting of increasing legalization. *Clinical Pediatric Emergency Medicine*, 18(3), 159-162.
- Vandrey, R., Raber, J. C., Raber, M. E., Douglass, B., Miller, C., & Bonn-Miller, M. O. (2015). Cannabinoid dose and label accuracy in edible medical cannabis products. *Journal of the American Medical Association Pediatrics*, 313(24), 2491–2493.
- Wang, G. S. (2017). Pediatric concerns due to expanded cannabis use: Unintended consequences of legalization. *Journal of Medical Toxicology*, 13(1), 99–105.
- Wang, G. S., Hall, K., Vigil, D., Banerji, S., Monte, A., & VanDyke, M. (2017). Marijuana and acute health care contacts in Colorado. *Preventive Medicine*, 104, 24–30.
- Wang, G. S., Le Lait, M. C., Deakyne, S. J., Bronstein, A. C., Bajaj, L., & Roosevelt, G. (2016). Unintentional pediatric exposures to marijuana in Colorado, 2009-2015. *Journal of the American Medical Association Pediatrics*, 170(9), e160971.
- Wang, G. S., Roosevelt, G., & Heard, K. (2013). Pediatric marijuana exposures in a medical marijuana state. *Journal of the American Medical Association Pediatrics*, 167(7), 630–633.
- Wang, G. S., Roosevelt, G., Le Lait, M. C., Martinez, E. M., Bucher-Bartelson, B., et al. (2014). Association of unintentional pediatric exposures with decriminalization of marijuana in the United States. *Annals of Emergency Medicine*, 63(6), 684–689.

## **Impact on Opioid Prescribing and Opioid-Related Mortality**

- Ashrafioun, L., Bohnert, K. M., Jannausch, M., & Ilgen, M. A. (2015). Characteristics of substance use disorder treatment patients using medical cannabis for pain. *Addictive Behaviors, 42*, 185-188.
- Bachhuber, M. A., Saloner, B., Cunningham, C. O., & Barry, C. L. (2014). Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. *Journal of the American Medical Association Internal Medicine, 174*(10), 1668-1673.
- Boehnke, K. F., Litinas, E., & Clauw, D. J. (2016). Medical cannabis use is associated with decrease opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. *Journal of Pain, 17*(6), 739-744.
- Bradford, A. C., Bradford, W. D., Abraham, A., & Adams, G. B. (2018). Association between U.S. state medical cannabis laws and opioid prescribing in the Medicare Part D population. *Journal of the American Medical Association Internal Medicine, 178*(5), 667-673.
- Bradford, A. C., & Bradford, W. D. (2017). Medical marijuana laws may be associated with a decline in the number of prescriptions for Medicaid enrollees. *Health Affairs, 36*(5), 945-951.
- Epstein, D. H., & Preston, K. L. (2015). No evidence for reduction of opioid-withdrawal symptoms by cannabis smoking during a methadone dose taper. *American Journal of Addictions, 24*(4), 323-328.
- Hayes, M. J., & Brown, M. S. (2014). Legalization of medical marijuana and incidence of opioid mortality. *Journal of the American Medical Association Internal Medicine, 174*(10), 1673-1674.
- Hurd, Y. L., Yoon, M., Manini, A. F., Hernandez, S., Olmedo, R., Ostman, M., et al. (2015). Early phase in the development of cannabidiol as a treatment for addiction: Opioid relapse takes initial center stage. *Neurotherapeutics, 12*(4), 807-815.
- Kim, J. H., Santaella-Tenorio, J., Mauro, C., Wrobel, J., Cerda, M., Keyes, K. M., et al. (2016). State medical marijuana laws and the prevalence of opioids detected among fatally injured drivers. *American Journal of Public Health, 106*(11), 2032-2037.
- Maher, D. P., Carr, D. B., Hill, K., McGeeney, B., Weed, V., Jackson, W. C., et al. (2017). Cannabis for the treatment of chronic pain in the era of an opioid epidemic: A symposium-based review of sociomedical science. *Pain Medicine Journal, 1-13*. Advance online publication. doi: 10.1093/pm/pnx143
- Nugent, S. M., Yarborough, B. J., Smith, N. X., Dobscha, S. K., Deyo, R. A., Green, C. A., et al. (2018). Patterns and correlates of medical cannabis use for pain among patients prescribed long-term opioid therapy. *General Hospital Psychiatry, 50*, 104-110.
- Olfson, M., Wall, M. M., Liu, S., & Blanco, C. (2018). Cannabis use and risk of prescription opioid use disorder in the United States. *American Journal of Psychiatry, 175*(1), 47-53.
- Piomelli, D., Weiss, S., Boyd, G., Pacula, R. L., & Cooper, Z. (2018). Cannabis and the opioid crisis. *Cannabis and Cannabinoid Research, 3*(1), 108-116.



- Powell, D., Pacula, R. L., & Jacobson, M. (2018). Do medical marijuana laws reduce addictions and deaths related to pain killers? *Journal of Health Economics*, 58, 29-42.
- Reiman, A., Welty, M., & Solomon, P. (2017). Cannabis as a substitute for opioid-based pain medication: Patient self-report. *Cannabis and Cannabinoid Research*, 2(1), 160-166.
- Sohler, N. L., Starrels, J., Khalid, L., Bachhuber, M., Arnsten, J., Nahvi, S., & et al. (2018). Cannabis use is associated with lower odds of prescription opioid analgesic use among HIV-infected individuals with chronic pain. *Substance Use & Misuse*, 53(10), 1602-1607.
- Vigil, J. M., Stith, S. S., Adams, I. M., & Reeve, A. P. (2017). Associations between medical cannabis and prescription opioid use in chronic pain patients: A preliminary cohort study. *PLoS ONE*, 12(11), 1-13. doi: 10.1371/journal.pone.0187795
- Vigil, J. M., Stith, S. S., & Reeve, A. P. (2018). Accuracy of patient opioid use reporting at the time of medical cannabis license renewal. *Pain Research and Management*, 4. doi:10.1155/2018/5704128
- Vyas, M. B., LeBaron, V. T., & Gilson, A. M. (2018). The use of cannabis in response to the opioid crisis: A review of the literature. *Nurse Outlook*, 66(1), 56-65.
- Wen, H. & Hockenberry, J. M. (2018). Association of medical and adult-use marijuana laws with opioid prescribing for Medicaid enrollees. *Journal of the American Medical Association Internal Medicine*, 178(5), 673-679.